Ipamorelin vs CJC-1295 + Ipamorelin
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor, the ghrelin receptor, and it has a small primary literature of its own: rodent and ferret pharmacology, one human pharmacokinetic-pharmacodynamic study, and one randomised phase 2 trial in postoperative ileus that did not separate from placebo. The pairing sold as CJC-1295 plus ipamorelin adds a long-acting analogue of growth hormone-releasing hormone to that same pentapeptide, on the argument that engaging two different receptors releases more growth hormone than either does alone. This comparison is unusual because one side contains the other. It therefore comes down to a single question: what does adding the growth hormone-releasing hormone analogue demonstrably do. No interventional study has ever administered the pairing, so the answer does not come from a trial of the combination. It comes from separate studies of each component and from older human work on entirely different molecules.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published interventional study has administered ipamorelin together with CJC-1295, and none has compared the pairing against ipamorelin alone. A PubMed query intersecting the two names returns ten records, and every one of them is a narrative or scoping review of unapproved peptides or an analytical method, with no trial among them. The most specific statement about the pairing in that set comes from a 2026 primer for orthopaedic and sports medicine physicians, which reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension in murine models of glucocorticoid-induced muscle loss and that the finding was limited to animal studies. The primary experiment behind that sentence is not identifiable among the thirty-three PubMed records that name CJC-1295, which otherwise consist of reviews, doping-control methods, product-quality analyses and the human pharmacology trials of the analogue itself. A doping-control paper sits at the other end of the same intersection: Kwok and colleagues developed an extraction and mass-spectrometry method that detected ipamorelin and CJC-1295 among seven peptides in horse plasma, which characterises both molecules analytically without administering either. The synergy argument for combining the two rests on human studies of growth hormone-releasing hormone given with a growth hormone-releasing peptide or with ghrelin, published between 1990 and 2001, in which the combined growth hormone response exceeded the sum of the separate responses. Those experiments used neither ipamorelin nor CJC-1295.
The 10 publications that cover both
- 01Review2026
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, et al. · The American Journal of Sports Medicine · narrative review of the most commonly encountered injectable peptides, with CJC-1295 plus ipamorelin evaluated as one of the named agents alongside BPC-157, thymosin beta-4, TB-500, tesamorelin and GHK-Cu
The review reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, and stated that these findings were limited to animal studies. The authors concluded that indications, dosing, frequency and duration remained unknown across the peptides examined, and that significant further safety and efficacy research was required before recommendations could be made.
- 02Review2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, et al. · Frontiers in Endocrinology · narrative review contrasting peer-reviewed pharmacology and clinical evidence with online self-administration protocols for growth hormone axis peptides
The review grouped CJC-1295, both with and without the drug affinity complex, among the growth hormone-releasing hormone analogues and ipamorelin among the growth hormone secretagogues, and stratified the class into evidence tiers running from regulatory-grade randomised data to a complete absence of human studies. It recorded endocrine and metabolic disturbances, fluid retention, musculoskeletal symptoms and injection-site reactions among reported adverse effects, and noted uncertainty about product composition and stacking practices in unregulated supply.
- 03Review2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Villegas Meza AD, et al. · JBJS Reviews · structured narrative review of human and translational evidence published between January 2020 and August 2025 for injectable peptides relevant to orthopaedics and sports medicine
The review identified five functional peptide classes and placed CJC-1295, ipamorelin and tesamorelin together as growth hormone axis secretagogues that remained investigational, with uncertain safety profiles, product quality concerns and widespread antidoping restrictions. Only glucagon-like peptide-1 receptor agonists were judged to be supported by reproducible randomised evidence within the review's scope.
- 04Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Medicine · narrative review of approved and unapproved peptides marketed direct to patients, covering CJC-1295, ipamorelin, sermorelin, tesamorelin, MOTS-c, AOD-9604, BPC-157, GHK-Cu and thymosin beta-4
The review reported that many unapproved peptides showed favourable tissue repair and metabolic outcomes in animal models while rigorous human safety data remained scarce and the potential for serious harm existed. It described a parallel grey market operating outside regulatory oversight and discussed the placebo effect, amplified by social media, as a mediator of perceived peptide efficacy.
- 05Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, et al. · Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews · mechanistic review of therapeutic peptides in orthopaedic injury, grouped by signalling pathway
The review grouped ipamorelin, CJC-1295, tesamorelin, sermorelin and AOD-9604 together as growth hormone secretagogues described as activating IGF-1 signalling and satellite cell repair. The authors stated that preclinical studies were promising but that clinical trials were currently lacking across the peptide classes reviewed.
- 06Review2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Tewari K, et al. · The American Journal of Sports Medicine · PRISMA-guided scoping review of PubMed records for six peptides, including CJC-1295 and ipamorelin, combined with musculoskeletal tissue search terms
The authors searched for animal and human evidence on each peptide for musculoskeletal recovery and enhancement, and reported that claimed benefits of the emerging peptide supplements remained unsubstantiated by current human trials despite promising animal findings. Cardiovascular and metabolic safety concerns were noted, as was the perception among patients and athletes that these compounds carry low risk.
- 07Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · International Journal of Molecular Sciences · review of 106 articles prioritising systematic reviews, meta-analyses and randomised trials, covering peptides used in metabolic, endocrine and aesthetic settings including CJC-1295 and ipamorelin
The review listed the drug affinity complex form of CJC-1295 alongside sermorelin and tesamorelin as growth hormone-releasing factor analogues, and included ipamorelin among the compounds surveyed. The authors concluded that several unapproved peptides had expanded rapidly into preventive medicine and performance enhancement and that further study was needed before most could be considered safe for human use.
- 08Review2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, et al. · Frontiers in Aging · narrative review searching PubMed, Scopus and regulatory databases through January 2026 for nine named peptides, with CJC-1295 and ipamorelin treated together under growth hormone modulation
The review identified growth hormone modulation, represented by CJC-1295 and ipamorelin, as one of nine peptide-based approaches to ageing hallmarks. The authors reported that non-approved peptides in the set showed promising preclinical and limited clinical evidence but lacked long-term safety data and systematic validation, and listed combination therapy effects among the significant knowledge gaps.
- 09Review2026
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, et al. · The Journal of Sports Medicine and Physical Fitness · critical review of peptide and peptide-analogue use in recreational and professional sport, naming ipamorelin among growth hormone secretagogues and CJC-1295 among growth hormone-releasing hormone analogues
The review reported that most published studies of these peptides examined therapeutic applications under controlled conditions rather than the supraphysiological or combined protocols common in bodybuilding, and that clinical evidence for use in sport was limited. It recorded cardiovascular strain, insulin resistance, dyslipidaemia and psychiatric instability among emerging risks, and noted that products from an unregulated supply chain were often mislabelled or contaminated.
- 10In vitro2013
Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry
Kwok WH, et al. · Analytical and Bioanalytical Chemistry · mixed-mode anion exchange solid-phase extraction with ultra-high-performance liquid chromatography and high-resolution mass spectrometry, applied to seven peptides including ipamorelin and CJC-1295 in horse plasma
Limits of detection below 50 pg/mL were estimated for all seven target peptides, and the method was validated for specificity, precision and recovery. In vitro metabolites were identified for each of the studied peptides other than the thymosin beta-4 fragment, which the authors described as a first for horses. Neither ipamorelin nor CJC-1295 was administered to an animal in the study; both were characterised analytically.
Side by side.
| Ipamorelin | CJC-1295 + Ipamorelin | |
|---|---|---|
| Evidence maturity | Early clinical | Early clinical |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 9 | 5 |
| Newest paper | 2026 | 2026 |
| Composition | A single defined molecule: a synthetic pentapeptide with an established sequence, molecular formula and identifier record. | A compounded pairing of that same pentapeptide with CJC-1295, a growth hormone-releasing hormone analogue. The name CJC-1295 is applied both to the albumin-binding drug affinity complex form studied in humans and to the unmodified releasing-factor fragment frequently sold under the same label, so the second component is not a single defined product. |
| Mechanism as described in the literature | Selective agonism at the growth hormone secretagogue receptor 1a, the ghrelin receptor, reported in 1998 to release growth hormone with potency comparable to an earlier releasing peptide while not raising ACTH or cortisol above the levels seen after releasing-hormone stimulation. | Two receptor pathways engaged at once: the ghrelin receptor and the growth hormone-releasing hormone receptor. The rationale is drawn from human studies in which a releasing peptide, or ghrelin itself, combined with growth hormone-releasing hormone produced a response greater than the sum of the separate responses. |
| Size of the evidence base | Small but real. Rodent bone and gastrointestinal motility work, a ferret model of chemotherapy-induced weight loss, a fish reproductive-axis study, one human pharmacokinetic-pharmacodynamic analysis and one randomised phase 2 trial. | Absent at the level of the combination. Ten indexed records name both peptides and all are reviews or analytical methods; the evidence available is component-level, comprising separate studies of each molecule and older work on unrelated releasing peptides. |
| Best-characterised finding | Growth hormone release without a significant rise in ACTH or cortisol, the selectivity result that named the compound, replicated in the original in vitro and in vivo work in rats and swine. | None specific to the pairing. The most specific published statement is a 2026 review's report of improved maximum tetanic tension in murine glucocorticoid-induced muscle loss, described by its authors as limited to animal studies. |
| Human data | A dose-escalation pharmacokinetic-pharmacodynamic study in healthy volunteers, and a randomised placebo-controlled phase 2 trial in 114 bowel resection patients in which the compound was well tolerated but did not differ significantly from placebo on time to first tolerated meal. | None for the pairing. The human data that exist belong to the components separately: the phase 2 ileus trial for the pentapeptide, and randomised ascending-dose and frequent-sampling studies of the drug affinity complex analogue in healthy adults. |
| Evidence maturity | Early clinical, and stalled. No randomised trial has demonstrated benefit on any efficacy endpoint, and development for the indication that reached phase 2 did not proceed. | Untested. The combination has not entered clinical development at all, so its evidence base is best described as absent rather than negative. |
| Product quality and safety signals | Long-term human safety, body composition effects and musculoskeletal outcomes are unstudied; the phase 2 trial reported tolerability without demonstrating efficacy. | Mass-spectrometric analysis of illicitly marketed growth-promoting preparations found discrepancies between declared and actual content, including incorrect peptide identity and unexpected analogues, so label content cannot be assumed to describe an unregulated two-peptide vial. |
| Regulatory and anti-doping status | No approved formulation anywhere. Growth hormone secretagogues are prohibited in sport, and detection methods for the pentapeptide exist in human and equine doping control. | No approved formulation, and the combination exists only as a compounded or grey-market product. Both components fall under prohibited-substance categories in sport as growth hormone-releasing agents. |
And what it does not.
The comparison reduces to whether adding a growth hormone-releasing hormone analogue to ipamorelin has been shown to do anything, and the published answer is that it has not been tested. Not tested and found equivalent, not tested and found inferior: never administered in a study at all. Every indexed paper naming both peptides is a review or an analytical method, and the reviews consistently describe the combination as an unapproved product whose clinical evidence base is missing rather than negative. Ipamorelin alone is not on strong ground either. Its selectivity result is well characterised in animals, its human pharmacology amounts to one modelling study, and its only randomised trial in patients did not separate from placebo on its primary endpoint. The synergy argument for the pairing is genuine physiology, demonstrated in humans between 1990 and 2001, but it was demonstrated with different molecules and with growth hormone release as the endpoint rather than any clinical outcome. Neither side of this comparison has controlled human evidence for body composition, recovery or performance.
Common questions.
- Has the CJC-1295 and ipamorelin combination ever been tested in a study?
No interventional study administering the two together has been published. A PubMed query intersecting both names returns ten records, all of which are narrative or scoping reviews of unapproved peptides, doping-control methods or product-quality analyses. The research entry for the combination in this library states the same conclusion: the evidence available is component-level, drawn from separate studies of each peptide and from older human work on co-administration of growth hormone-releasing hormone with other secretagogues.
- Where does the synergy claim for the pairing come from?
From human endocrine studies conducted long before either compound was marketed. A 1990 study in normal men reported that a growth hormone-releasing peptide combined with growth hormone-releasing hormone produced a growth hormone response greater than the sum of the individual responses, and a 2001 crossover study extended the same observation to ghrelin, the natural ligand. Those experiments used neither ipamorelin nor CJC-1295, and their endpoint was hormone release rather than any clinical outcome, so the extension to this pairing is an argument by analogy.
- Is the CJC-1295 studied in humans the same molecule sold under that name?
Frequently not. The human trials that established prolonged growth hormone and IGF-1 elevation used the form carrying a drug affinity complex, which binds albumin and extends its duration of action. The unmodified releasing-factor fragment is commonly sold under the same name, and reviews of the field distinguish CJC-1295 with and without the complex explicitly. The research entry for the combination lists this substitution among its evidence gaps.
- What did the only randomised trial of ipamorelin in patients find?
It did not meet its primary endpoint. A randomised placebo-controlled phase 2 proof-of-concept study in 114 patients recovering from bowel resection reported that the compound was well tolerated but produced no statistically significant difference from placebo in time to first tolerated meal. The endpoints were gastrointestinal, reflecting ghrelin receptor effects on motility rather than growth hormone release, and development for that indication did not continue.
- Can label content be relied on for an unregulated two-peptide vial?
The published analytical work suggests caution. Mass-spectrometric characterisation of illicitly distributed growth-promoting preparations found discrepancies between declared and actual content, including incorrect peptide identity, unexpected analogues and variable amounts. Reviews of peptide use in sport make the same point, describing an unregulated supply chain in which products are often mislabelled or contaminated. Doping-control laboratories have published methods capable of detecting both peptides in plasma, which is the context in which most analytical characterisation of these molecules has been performed.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.